Table 2. Xenograft study design.
| Group | Number of animals | Test article | Dose | Route of administration | Schedule |
|---|---|---|---|---|---|
| 1 | 4 | Vehicle (0.6%Pluronic F-68 and 0.6%PVP K29/32) | 0.1 ml/10 g | PO | MWF |
| 2 | 4 | Selinexor | 2.5 mg/kg | PO | MWF |
| 3 | 4 | Cisplatin | 4 mg/kg | IP | Q7D |
| 4 | 4 | Docetaxel | 4 mg/kg | IP | Q7D |
| 5 | 4 | CisplatinSelinexor | 4 mg/kg2.5 mg/kg | IPPO | Q7DMWF |
| 6 | 4 | DocetaxelSelinexor | 4 mg/kg2.5 mg/kg | IPPO | Q7DMWF |
24 nu/nu mice were allocated to six groups of four mice such that the mean tumor volume in each group was within the range of 161–172 mm3. Mice were treated with vehicle, selinexor, cisplatin and docetaxel. Abbreviations: PO, oral; IP, intraperitoneal; MWF, Monday, Wednesday and Friday; Q7D, daily for 7 days.